Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Gensia's GenESA receives approval in the U.K.

Gensia's GenESA receives approval in the U.K.

Gensia Inc. on Friday said it received U.K. approval of its GenESA System to pharmacologically stress the heart. The system, which uses computer-controlled delivery of arbutamine, is indicated for use in the diagnosis of coronary artery disease in conjunction with electrocardiography (ECG), echocardiography and radionuclide imaging for patients who can't exercise adequately.

GNSA's Gensia Europe Ltd. subsidiary plans to begin sales late this quarter or early in the second quarter

Read the full 791 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE